Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-12-08
2000-08-29
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
A61K 31495, A61K 3150
Patent
active
061109150
ABSTRACT:
A class of substituted 7,8-ring fused 1,2,4-triazolo[4,3-b]pyridazine derivatives, as shown in Formula I, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position and a substituted alkoxy moiety at the 6-position, are selective ligands for GABA.sub.A receptors, in particular having high affinity for the .alpha.2 and/or .alpha.3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of emesis. ##STR1##
REFERENCES:
patent: 4112095 (1978-09-01), Allen, Jr. et al.
patent: 4117130 (1978-09-01), Allen, Jr. et al.
patent: 4230705 (1980-10-01), Allen, Jr. et al.
patent: 4260755 (1981-04-01), Moran et al.
patent: 4260756 (1981-04-01), Moran et al.
patent: 4654343 (1987-03-01), Albright et al.
Ross, Chapter 2 in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press, pp. 33-35, 1990.
Castro Pineiro Jose Luis
Tattersall Frederick David
Lee Shu M.
Liu Hong
Merck & Co. , Inc.
Rose David L.
Shah Mukund J.
LandOfFree
Antiemetic use of triazolo-pyridazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiemetic use of triazolo-pyridazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiemetic use of triazolo-pyridazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1250075